N/A N=360 Participate While Pregnant Survey
Pregnancy
Primary: Willingness to Participate in Research While Pregnant — 319; 39; 288; 70 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=348 To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
SARS-CoV-2 Infection · COVID-19 · Maternal Immunization
Primary: Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1 — 2.5; 0.6; 0.6; 0 Percentage of participants
N/A N=1,195 Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
HIV-I Infection
Primary: Participants Initiating Pre-exposure Prophylaxis During Pregnancy — 1089 Participants
N/A N=305 Boostrix® Pregnancy Registry
Pertussis
Primary: Number of Participants With Known Pregnancy Outcomes, by Type of Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Boostrix During Pregnancy…
N/A N=70 Using Mental Imagination to Prevent Excessive Gestational Weight Gain in Overweight and Obese Pregnant Women
Obesity · Weight Gain, Maternal
Primary: Percent Change in Body Weight — 10.9; 9.6 percentage change
N/A N=150 Psychological Impact of Pregnancy of Unknown Location
Pregnancy of Unknown Location · Ectopic Pregnancy · Anxiety
Primary: Psychological Morbidity — 10; 10; 5; 5 score on a scale
Phase 2 N=370 S. Japonicum and Pregnancy Outcomes
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Phase 4 N=687 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
Diphtheria-Tetanus-acellular Pertussis Vaccines
Primary: Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples…
N/A N=117 Happy Mother - Healthy Baby: Supplement Study on Biological Processes Underlying Anxiety During Pregnancy
Anxiety
Primary: Peripheral Markers of Inflammation — 17.09; 20.22; 14.79; 11.78 pg/ml
N/A N=30 The MOTHER (Mobile Technologies to Help Enhancing Regular Physical Activity) Trial for Pregnant Women
Physical Activity
Primary: Physical Activity Monitor Measured Steps — 1166.6; 1062.6; 1092.1; 804.3 step
N/A N=20 Patient Centered Postpartum Contraception App
Contraceptive Usage
Primary: Feasibility of Application — 4.47; 4.52; 4.16; 4.26 units on a scale
Phase 2 N=120 H1N1 Vaccine in Pregnant Women
Influenza
Primary: Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination — 15; 21; 26; 37 Participants
N/A N=881 Understanding COVID-19 Infection in Pregnant Women and Their Babies
Corona Virus Infection · Pregnancy Related · Neonatal Infection
Primary: Antibody Concentrations in Maternal Blood in Pregnant Women in England — 37.2; 7.2; 80.3; 590.5 CAU/ml
N/A N=51 Sedentary Behavior Reduction in Pregnancy Intervention Study
Pregnancy Complications · Sedentary Behavior
Primary: Sedentary Time — 10.42; 10.52; 9.62; 10.38 total hours/day — p=<0.05
N/A N=6,894 Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
COVID-19 · Pregnancy Complications · Mental Health Wellness 1
Primary: Number of Participants With Symptoms of Post-traumatic Stress Disorder — 1028; 532 Participants
N/A N=16 Acute Exercise Effects in Obese Pregnancy
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
Phase 3 N=4 ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection
Infection, Human Immunodeficiency Virus · HIV Infections · Arthralgia
Primary: Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir — 55.045; 42.473; 78.917 Micrograms*hours per…
N/A N=312 Optimizing Health From Pregnancy Through One Year Postpartum
Obesity · Pregnancy Related
Primary: Maternal Weight — 196.59; 201.03; 193.70; 201.66 pounds — p=.80
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
N/A N=103 Twinrix Pregnancy Registry
Hepatitis
Primary: Number of Outcomes From Pregnancies With Reported Exposure Within 28 Days of Last Menstrual Period — 0; 0; 0; 0 Pregnancy Outcomes
Phase 2 N=102 Influenza Vaccine in Pregnant Women
Influenza
Primary: Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against Each Antigen Included in the 2008-2009…
N/A N=2 Safety of 4CMenB Exposure During Pregnancy
Infections, Meningococcal
Primary: Major Congenital Malformation (MCM)
N/A N=166 PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
Pregnancy
Primary: Number of Recruited Eligible Pregnant Women <20 Weeks Gestational Age — 166 Participants
Phase 2 N=84 Novartis H1N1 Vaccine in Pregnant Women
Influenza
Primary: Number of Participants Reporting Maternal Complications of Pregnancy, Labor and Delivery — 0; 0; 0; 0 participants
Phase 2 N=51 A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
COVID-19 Prevention
Primary: Number of Adult Participants With Solicited Local Adverse Events (AEs) for 7 Days Post First Vaccination — 10; 5; 20 Participants
Phase 2 N=50 Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
Tuberculosis
Primary: Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT) for Intensive and Sparse PK — 1.4; 1.50 L/hr
N/A N=113 Emotion-Diet Interactions in Pregnancy
Pregnancy Related · Stress, Psychological · Glucose Intolerance During Pregnancy
Primary: Postprandial Glycemic Response With Stress Exposure — 12998.83; 12833.69 mg/dl * minutes
Phase 1 N=7 Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women
HIV Infections · Pregnancy Related
Primary: Maximum Observed Plasma Concentration (Cmax) of Doraviraine During Pregnancy — 1340; 928; 1060; 252 ng/mL — p=0.400
Phase 3 N=77 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
HIV · HIV Infections · Pregnancy
Primary: Predose (Trough) Plasma Concentration (C0h) — 3608; 491.4; 2481; 147 nanogram per milliliter (ng/mL)
Phase 3 N=39 PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
Hiv
Primary: Tenofovir Diphosphate (TFV-DP) Levels in Plasma and Intracellular Levels in Pregnant Women on Daily PrEP — 580; 71 TFV-DP PBMC (fmol/10^6cells)